Our vision is that the OpenDNA precision medicine AI platform will allow physicians to replace trial and error treatment strategies with precision care at reduced cost.
Our first clinical application is cardiometabolic syndrome, affecting about 1 billion patients worldwide, which includes diabetes, hypertension, elevated cholesterol and obesity, and leads to major cardiovascular, kidney and other complications. People with cardiometabolic syndrome are twice as likely to die from cardiovascular disease, resulting in about 5 million deaths annually, and an economic burden of up to $73 billion in the US alone and $286 billion globally.
OpenDNA is in the process of validating its cardiometabolic syndrome solution in pilot studies, and then will apply the technology to other conditions such as cancer, autoimmune and musculoskeletal disease.
https://www.open-dna.com/
Our first clinical application is cardiometabolic syndrome, affecting about 1 billion patients worldwide, which includes diabetes, hypertension, elevated cholesterol and obesity, and leads to major cardiovascular, kidney and other complications. People with cardiometabolic syndrome are twice as likely to die from cardiovascular disease, resulting in about 5 million deaths annually, and an economic burden of up to $73 billion in the US alone and $286 billion globally.
OpenDNA is in the process of validating its cardiometabolic syndrome solution in pilot studies, and then will apply the technology to other conditions such as cancer, autoimmune and musculoskeletal disease.
https://www.open-dna.com/
Location: Israel
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | MindUP | mindup.co.... |
Mentions in press and media 2
| Date | Title | Description |
| 02.12.2024 | OpenDNA Expands CardioRisk+ Genetic Testing Panel to Include Obesity Risk | GAITHERSBURG, MD, UNITED STATES, December 2, 2024 /EINPresswire.com/ -- OpenDNA, a leading provider of advanced genetic testing solutions, today announced the launch of a new genetic test for obesity, which will be added to its comprehensiv... |
| 09.03.2022 | OpenDNA announces know-how and research agreement with Mayo Clinic as part of pilot clinical study for cardiovascular disease prevention | OpenDNA We are excited to collaborate with Mayo Clinic with the aim to bring forth a new precision medicine approach to predict and treat complex polygenic diseases TEL AVIV, Israel (PRWEB) March 09, 2022 OpenDNA, providers of a precision m... |